Loading
A phase 3 trial of Trastuzumab deruxtecan in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Daiichi Sankyo, now recruiting.
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer is a phase 3 interventional study registered as NCT05950945 by Daiichi Sankyo, with 250 participants planned, started 2023-12-30 and due to reach its primary completion in 2027-10-01. Interventions recorded: Trastuzumab Deruxtecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-low and HER2-ultralow metastatic breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/